Journal of Advanced Pharmaceutical Technology & Research

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 10  |  Issue : 3  |  Page : 138--142

A questionnaire-based study to assess the status and perspective of fixed-dose combination among the various stakeholders including regulators, clinicians, researchers, and industry


Krishan Kumar Bhardwaj1, K Bangarurajan3, Tanveer Naved3, Satyendra Kumar Rajput2 
1 Central Drugs Standard Control Organization, Ghaziabad; Central Drugs Standard Control Organization, Ghaziabad, Director General of Health Services, MoHFW, Government of India, New Delhi, India
2 Center for Pharmacology and Toxicology, Amity Institute of Indian System of Medicines, Amity University, Noida, Uttar Pradesh, India

Correspondence Address:
Mr. Krishan Kumar Bhardwaj
Center for Drug and Regulatory Affair, Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh
India

Fixed-dose combinations (FDCs) dominating the global market because of better compliance. However, irrational combination can lead to human-made menace in terms of development of resistance, tolerance, drug abuse, and economy encumbrance. The US Food and Drug Administration defines a combination product as “a product composed of any combination of a drug and a device or a biological product and a device or a drug and a biological product or a drug, device, and a biological product.” Unfortunately, many FDC being introduced in India are usually irrational. The need for the present study arises as the Indian drug regulatory system has been oscillating between central drug authorities versus state drug regulatory authorities. To assess the same fifty-six regulators and 70 other stakeholders including researchers, clinician, and industry people have exposed to 14 questions, and the same are used to get the insights of FDC among producers and consumers. All data were analyzed using Sigma plot Software. Data was presented in the form of percentage of response (responders vs. nonresponders, agree vs. disagree, yes vs. no). Most of the stakeholders (99%) stressed on Rule 122 to be strictly followed and same should be disseminated among all the stakeholders. Similarly, it was emphasized by more than 95% stakeholders that FDC contents should be tested as per official pharmacopoeia.


How to cite this article:
Bhardwaj KK, Bangarurajan K, Naved T, Rajput SK. A questionnaire-based study to assess the status and perspective of fixed-dose combination among the various stakeholders including regulators, clinicians, researchers, and industry.J Adv Pharm Technol Res 2019;10:138-142


How to cite this URL:
Bhardwaj KK, Bangarurajan K, Naved T, Rajput SK. A questionnaire-based study to assess the status and perspective of fixed-dose combination among the various stakeholders including regulators, clinicians, researchers, and industry. J Adv Pharm Technol Res [serial online] 2019 [cited 2021 Dec 7 ];10:138-142
Available from: https://www.japtr.org/article.asp?issn=2231-4040;year=2019;volume=10;issue=3;spage=138;epage=142;aulast=Bhardwaj;type=0